ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Study Summary

The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive tumors and in combination with trastuzumab, and chemotherapy in participants with advanced-stage HER2-positive colorectal cancer and breast cancer.

Conditions

HER2-positive Breast Cancer HER2-positive Gastric Cancer HER2 Positive Solid Tumors HER2 Amplification Colorectal Cancer

Interventions / Drugs

ELVN-002 Trastuzumab 5-Fluorouracil Oxaliplatin Capecitabine Eribulin paclitaxel Leucovorin

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment275 participants

Primary Completion—

Lead SponsorEnliven Therapeutics

Data Retrieved2026-04-11 04:12:48.346176+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.